Browse studies

Find your next paid study

3,843 recruiting studies matching your filters

National Liver Cancer Screening Trial

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients…

Carcinoma, HepatocellularLiver CancerLiver Cirrhosis+1 more

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT06084234

Phase 2

Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer

The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone re…

Triple Negative Breast Cancer

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT05528133

Phase 3

Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial

This phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leuc…

Metastatic Appendix CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+3 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07271355

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have…

Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more

Estimated

~$10 – $1,125

AstraZenecaNCT07124000

Phase 3

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compar…

Triple-Negative Breast Cancer

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06393374

Observational

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in Triple Negative Breast Cancer (TNBC)

The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative b…

Triple Negative Breast Cancer

Estimated

~$10 – $6,250

Yale UniversityNCT07066189

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to…

Medullary Thyroid Cancer (MTC)Cultural Adaptation

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07142005

Phase 2

Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination wi…

Breast Cancer, Metastatic

Estimated

~$10 – $8,750

ALX Oncology Inc.NCT07007559

Phase 1

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treat…

Metastatic Prostate Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07181161

Phase 2

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamo…

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more

Phase 1

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, ph…

Advanced Solid TumorsColorectal Cancer

Estimated

~$10 – $8,750

Vividion Therapeutics, Inc.NCT06004245

Phase 3

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in parti…

Metastatic Castration-Resistant Prostate Cancer

Estimated

~$10 – $7,500

PfizerNCT06629779